Fintel reports that on May 12, 2025, Maxim Group initiated coverage of ProMIS Neurosciences (NasdaqCM:PMN) with a Buy recommendation.
Analyst Price Forecast Suggests 1,322.31% Upside
As of May 7, 2025, the average one-year price target for ProMIS Neurosciences is $7.14/share. The forecasts range from a low of $6.06 to a high of $8.40. The average price target represents an increase of 1,322.31% from its latest reported closing price of $0.50 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for ProMIS Neurosciences is 0MM, a decrease of NaN%. The projected annual non-GAAP EPS is -1.92.
What is the Fund Sentiment?
There are 23 funds or institutions reporting positions in ProMIS Neurosciences. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to PMN is 0.18%, an increase of 28.44%. Total shares owned by institutions decreased in the last three months by 4.01% to 9,719K shares.
What are Other Shareholders Doing?
Great Point Partners holds 2,645K shares representing 8.09% ownership of the company. In its prior filing, the firm reported owning 2,791K shares , representing a decrease of 5.50%. The firm increased its portfolio allocation in PMN by 15.07% over the last quarter.
Armistice Capital holds 2,510K shares representing 7.68% ownership of the company. In its prior filing, the firm reported owning 2,670K shares , representing a decrease of 6.38%. The firm decreased its portfolio allocation in PMN by 39.20% over the last quarter.
Sphera Funds Management holds 1,929K shares representing 5.90% ownership of the company. No change in the last quarter.
Ally Bridge Group holds 1,593K shares representing 4.87% ownership of the company. No change in the last quarter.
Altium Capital Management holds 574K shares representing 1.76% ownership of the company. In its prior filing, the firm reported owning 581K shares , representing a decrease of 1.24%. The firm increased its portfolio allocation in PMN by 483.55% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
